title: Midterm results from the TRAVIATA registry: treatment of thoracic aortic disease with the valiant stent graft.
abstract: OBJECTIVE
  To assess early and midterm outcomes after thoracic endovascular aortic repair (TEVAR) with the Valiant Thoracic Stent Graft.
  
  
  METHODS
  Data were reviewed retrospectively for 92 patients (69 men; mean age 65+/-14.5 years) who underwent TEVAR in 52.2% elective and 47.8% urgent/emergent procedures for treatment of 56 degenerative aneurysms, 32 aortic dissections, and 4 traumatic injuries at 4 German centers between June 2005 and March 2008.
  
  
  RESULTS
  The technical success rate was 86.9%. Through 30 days, there were 3 (3.3%) deaths. Periprocedural complications included endoleak (n = 6), systemic complications (n = 6), arterial rupture or dissection (n = 6), device-related complications (n = 5), retrograde aortic dissection (n = 1), aortic rupture (n = 1), spinal cord ischemia (n = 1), and stroke (n = 1). Cumulative survival was 95.5% at 1 year, 87.4% at 2 years, and 76.4% at 3 years. The rate of aneurysm-related mortality was 2.2% (n = 2). For aneurysm and dissection patients, respectively, the rates of major complications were 9.3% and 15.6%, and secondary procedures were required in 7.4% and 12.5%. Type I endoleaks were detected in 4 aneurysm and 2 dissection patients, and graft migration occurred in 1 patient each from the aneurysm and dissection groups. No patients were converted to open surgery during follow-up. Aortic diameter reduction >5 mm was confirmed for 58.4% of patients overall.
  
  
  CONCLUSIONS
  The high technical and clinical success, the low all-cause and aneurysm-related mortality, the negligible rates of neurological complications and spinal cord ischemia, and the low incidence of endoleak support the safety and effectiveness of TEVAR with the Valiant Thoracic Stent Graft. However, some deployment-related complications could be avoided by enhancements of the deployment mechanism.
authors.affiliation: Department of Vascular Surgery, St Franziskus-Hospital GmbH, and Center for Vascular and Endovascular Surgery, University of Münster, Germany. giovanni.torsello@sfh-muenster.de
authors.forename: Giovanni B
authors.initials: GB
authors.lastname: Torsello
authors.forename: Giovanni F
authors.initials: GF
authors.lastname: Torsello
authors.forename: Nani
authors.initials: N
authors.lastname: Osada
authors.forename: Omke E
authors.initials: OE
authors.lastname: Teebken
authors.forename: Christoph-Maria
authors.initials: CM
authors.lastname: Ratusinski
authors.forename: Christoph A
authors.initials: CA
authors.lastname: Nienaber
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017130:Angioplasty; D001013:Aorta, Thoracic; D001018:Aortic Diseases / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation; D002648:Child; D015331:Cohort Studies; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D012042:Registries; D012189:Retrospective Studies; D015607:Stents; D016896:Treatment Outcome; D055815:Young Adult